DK2121138T3 - Terapeutiske anvendelser af eslicarbazepin - Google Patents

Terapeutiske anvendelser af eslicarbazepin

Info

Publication number: DK2121138T3
Authority: DK; Denmark
Prior art keywords: eslicarbazepine; therapeutic uses; therapeutic
Prior art date: 2007-01-15

Application number

DK08705172.8T

Other languages

English (en)

Inventor

DA SILVA PATRÃCIO MANUEL VIEIRA ARAÃºJO SOARES

Original Assignee

Bial - Portela & Ca S A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-01-15

Filing date

2008-01-14

Publication date

2017-01-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37809995&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2121138(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-01-14 Application filed by Bial - Portela & Ca S A filed Critical Bial - Portela & Ca S A

2017-01-02 Application granted granted Critical

2017-01-02 Publication of DK2121138T3 publication Critical patent/DK2121138T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Virology (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK08705172.8T 2007-01-15 2008-01-14 Terapeutiske anvendelser af eslicarbazepin DK2121138T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0700773.5A GB0700773D0 (en)	2007-01-15	2007-01-15	Drug therapies
PCT/PT2008/000002 WO2008088233A1 (en)	2007-01-15	2008-01-14	Therapeutical uses of eslicarbazepine

Publications (1)

Publication Number	Publication Date
DK2121138T3 true DK2121138T3 (da)	2017-01-02

Family

ID=37809995

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK08705172.8T DK2121138T3 (da)	2007-01-15	2008-01-14	Terapeutiske anvendelser af eslicarbazepin

Country Status (27)

Country	Link
US (3)	US20100048538A1 (da)
EP (2)	EP2121138B1 (da)
JP (1)	JP2010515727A (da)
KR (1)	KR101519040B1 (da)
CN (1)	CN101605571A (da)
AR (1)	AR064898A1 (da)
AU (1)	AU2008205712B2 (da)
BR (1)	BRPI0806568A2 (da)
CA (1)	CA2674303C (da)
CY (1)	CY1118297T1 (da)
DK (1)	DK2121138T3 (da)
ES (1)	ES2606952T3 (da)
GB (1)	GB0700773D0 (da)
HR (1)	HRP20161619T1 (da)
HU (1)	HUE032467T2 (da)
IL (1)	IL199697A0 (da)
LT (1)	LT2121138T (da)
MX (1)	MX2009007486A (da)
NZ (1)	NZ578331A (da)
PL (1)	PL2121138T3 (da)
PT (1)	PT2121138T (da)
RS (1)	RS55475B1 (da)
RU (1)	RU2488397C2 (da)
SI (1)	SI2121138T1 (da)
UA (1)	UA98133C2 (da)
WO (1)	WO2008088233A1 (da)
ZA (1)	ZA200905468B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060252745A1 (en)	2005-05-06	2006-11-09	Almeida Jose L D	Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0700773D0 (en)	2007-01-15	2007-02-21	Portela & Ca Sa	Drug therapies
WO2011014084A1 (en)	2009-07-27	2011-02-03	Bial - Portela & Ca., S.A.	Use of 5h-dibenz / b, f/ azepine-5-carboxamide derivatives for treating fibromyalgia
TR201008460A1 (tr)	2010-10-15	2012-05-21	Sanovel İlaç San.Ve Ti̇c.A.Ş.	Eslikarbazepinin saşe formülasyonları.
EP2747770A1 (en)	2011-08-26	2014-07-02	BIAL - Portela & Cª S.A.	Treatments involving eslicarbazepine acetate or eslicarbazepine
US11116737B1 (en)	2020-04-10	2021-09-14	University Of Georgia Research Foundation, Inc.	Methods of using probenecid for treatment of coronavirus infections
US11883529B2 (en) *	2020-08-28	2024-01-30	Medtronic, Inc.	Methods of administering anti-epilepsy agents and transport inhibitors to a subject

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB864536A (en)	1957-11-06	1961-04-06	Sapos S A Lab	ª‡-ethyl-phenylacetylurea
GB1028234A (en)	1964-01-06	1966-05-04	Ici Ltd	New pharmaceutical compositions comprising 5-aminodibenzocycloheptene derivatives
CH500196A (de) *	1969-03-10	1970-12-15	Ciba Geigy Ag	Verfahren zur Herstellung von neuen Azepinderivaten
CH505101A (de)	1969-03-31	1971-03-31	Ciba Geigy Ag	Verfahren zur Herstellung von neuen Azepinderivaten
US3637661A (en)	1970-03-04	1972-01-25	Ciba Geigy Corp	10-hydroxy-10 11-dihydro-dibenzazepine derivative
CH605791A5 (da)	1974-09-27	1978-10-13	Ciba Geigy Ag
US4235895A (en)	1978-11-10	1980-11-25	Ciba-Geigy Corporation	Substituted 5H-dibenz[b,f]azepine
FI75561C (fi)	1979-10-30	1988-07-11	Ciba Geigy Ag	Foerfarande foer framstaellning av 5- karbamoyl-10-oxo-10,11-dihydro-5h-dibens/b,f/azepin och daertill noedvaendiga mellanprodukter.
CH649080A5 (de)	1981-04-16	1985-04-30	Ciba Geigy Ag	5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
AU2929489A (en)	1987-12-22	1989-07-19	John W. FERKANY	Dextrorphan potentiator for anticonvulsant composition and method
EP0435826A1 (de)	1989-12-27	1991-07-03	Ciba-Geigy Ag	Intravenöse Lösungen für Status Epilepticus
US5827819A (en)	1990-11-01	1998-10-27	Oregon Health Sciences University	Covalent polar lipid conjugates with neurologically active compounds for targeting
RU2079304C1 (ru)	1990-11-08	1997-05-20	Фудзисава Фармасьютикал Ко., Лтд.	Фармацевтическая композиция, обладающая иммуносупрессорной и антимикробной активностями
CA2054983A1 (en)	1990-11-08	1992-05-09	Sotoo Asakura	Suspendible composition and process for preparing the same
US5095033A (en)	1991-03-01	1992-03-10	Laboratoires Biocodex	Method for treating epilepsy
FR2699077B1 (fr)	1992-12-16	1995-01-13	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr)	1993-03-05	1995-04-07	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement du neuro-sida.
IT1261808B (it)	1993-07-06	1996-06-03		Impiego di l-carnitina o acido l-carnitine e valproato nel trattamentodei disosrdini convulsivi
US5472714A (en)	1993-09-08	1995-12-05	Ciba-Geigy Corporation	Double-layered oxcarbazepine tablets
CA2575042A1 (en)	1994-04-28	1995-11-09	Alza Corporation	Effective dosage form for antiepileptic drugs
US20030056896A1 (en)	1995-05-12	2003-03-27	Frank Jao	Effective therapy for epilepsies
US5466683A (en)	1994-08-25	1995-11-14	Teva Pharmaceutical Industries Ltd.	Water-soluble analogs of carbamazepine
PT101732B (pt) *	1995-06-30	1997-12-31	Portela & Ca Sa	Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
IT1283594B1 (it)	1996-04-12	1998-04-22	Trifarma Srl	Derivati della 5h-dibenz- (b,f)-azepin-5-carbossiammide, loro preparazione e uso come sostanze ad azione medicinale
WO1998017692A1 (en)	1996-10-19	1998-04-30	University Of Wales, Bangor	Preparation of chemically reactive polysaccharides
US6296873B1 (en)	1997-01-23	2001-10-02	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Zero-order sustained release delivery system for carbamazephine derivatives
US5980942A (en)	1997-01-23	1999-11-09	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Zero-order sustained release matrix tablet formulations of carbamazepine
CO4920215A1 (es)	1997-02-14	2000-05-29	Novartis Ag	Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
IL125244A (en)	1998-07-07	2002-12-01	Yissum Res Dev Co	Pharmaceutical compositions containing low-melting waxes
CA2356460A1 (en)	1998-12-23	2000-06-29	Cytoscan Sciences L.L.C.	Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders
CA2370030C (en)	1999-04-09	2007-08-14	Euro-Celtique S.A.	Sodium channel blocker compositions and the use thereof
WO2000066096A2 (en)	1999-04-30	2000-11-09	Merab Lomia	Use of antiepileptics for treating respiratory disorders, in particular asthmatic disorders
US6420369B1 (en)	1999-05-24	2002-07-16	Ortho-Mcneil Pharmaceutical, Inc.	Anticonvulsant derivatives useful in treating dementia
EP1185488A1 (fr)	1999-06-15	2002-03-13	Rhodia Chimie	Sulfonylamides et carboxamides et leur application en catalyse asymetrique
US20020147197A1 (en) *	1999-10-08	2002-10-10	Newman Michael J.	Methods and compositions for enhancing pharmaceutical treatments
GB9925962D0 (en)	1999-11-02	1999-12-29	Novartis Ag	Organic compounds
JP4249415B2 (ja)	1999-12-01	2009-04-02	ユセベ，ソシエテアノニム	Ｃｎｓ疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物
GB9930058D0 (en)	1999-12-20	2000-02-09	Novartis Ag	Organic compounds
US20010036943A1 (en)	2000-04-07	2001-11-01	Coe Jotham W.	Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6191117B1 (en)	2000-07-10	2001-02-20	Walter E. Kozachuk	Methods of producing weight loss and treatment of obesity
AU2001282886A1 (en)	2000-07-13	2002-01-30	Pharmacia Corporation	Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
RU2178298C1 (ru)	2000-12-20	2002-01-20	Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева	Способ лечения больных с резистентными к фармакотерапии формами эпилепсии
GB0111566D0 (en)	2001-05-11	2001-07-04	Portela & Ca Sa	Method for preparation of (s)-(+)-and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azephine-5-carboxamide
US20040197402A1 (en)	2001-05-18	2004-10-07	Ashish Sehgal	Oxcarbazepine dosage forms
GB0112812D0 (en)	2001-05-25	2001-07-18	Portela & Ca Sa	Mthd for preparation of 10, 11-dihydro-10-hydroxy-5H-dibenz/B,F/azepine-5-c arboxamide and 10,11-dihydro-10-oxo-5H-dibenz/B,F/azepine-5-carb oxamide therefrom
GB0113663D0 (en) *	2001-06-05	2001-07-25	Novartis Ag	Use of organic compounds
RU2236224C2 (ru)	2001-10-16	2004-09-20	Российский научно-исследовательский нейрохирургический институт им. проф. А.Л. Поленова	Способ лечения эпилепсии
MXPA04004470A (es)	2001-11-12	2005-05-16	Novartis Ag	Monohidroxicarbamazepina para utilizarse en la preparacion de un medicamento para el tratamiento de un trastorno afectivo y de la atencion y dolor neuropatico.
EP1478400A1 (en)	2002-02-26	2004-11-24	Ortho-McNeil Pharmaceutical, Inc.	Therapy for the treatment of migraine comprising anticonvulsant derivatives and antimigraine agents
US20070021356A1 (en)	2002-03-18	2007-01-25	Cady Roger K	Preemptive prophlyaxis of migraine
CA2485932A1 (en)	2002-05-31	2003-12-11	Desitin Arzneimittel Gmbh	Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
DE10224170A1 (de)	2002-05-31	2003-12-11	Desitin Arzneimittel Gmbh	Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
BR0313230A (pt)	2002-08-06	2005-07-12	Novartis Ag	Uso de carboxamidas para o tratamento de tinido
US20040038874A1 (en)	2002-08-22	2004-02-26	Osemwota Omoigui	Method of treatment of persistent pain
GB0221956D0 (en)	2002-09-20	2002-10-30	Novartis Ag	Organic compounds
GB0223224D0 (en)	2002-10-07	2002-11-13	Novartis Ag	Organic compounds
CA2497780A1 (en)	2002-10-17	2004-04-29	Novartis Ag	Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors
US20040185097A1 (en)	2003-01-31	2004-09-23	Glenmark Pharmaceuticals Ltd.	Controlled release modifying complex and pharmaceutical compositions thereof
EP1594515A4 (en)	2003-02-03	2009-05-27	Supernus Pharmaceuticals Inc	FORMULATION AND ADMINISTRATION OF A MEDICINAL PRODUCT USING METHYLATED CRYSTALLINE CYCLODEXTRINS
GB0303615D0 (en)	2003-02-17	2003-03-19	Novartis Ag	Use of organic compounds
EP1596866A2 (en)	2003-02-17	2005-11-23	Novartis AG	Use of s-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
TW200501962A (en)	2003-04-01	2005-01-16	Novartis Ag	Use of carbamazepine derivatives for the treatment of agitation in dementia patients
TW200502222A (en)	2003-04-02	2005-01-16	Novartis Ag	Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
GB0307860D0 (en)	2003-04-04	2003-05-14	Novartis Ag	Organic compounds
GB2401605A (en)	2003-05-12	2004-11-17	Portela & Ca Sa	Method for racemisation of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide and optically enriched mixtures thereof
WO2004100992A2 (en)	2003-05-16	2004-11-25	Pfizer Products Inc.	Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
WO2004103348A2 (en)	2003-05-19	2004-12-02	Baxter International Inc.	Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
EP1658065A2 (en)	2003-08-29	2006-05-24	Allergan, Inc.	Using selective antagonists of persistent sodium current to treat neurological disorders and pain
WO2005020968A2 (en)	2003-09-03	2005-03-10	Novartis Ag	Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
KR100557093B1 (ko) *	2003-10-07	2006-03-03	한미약품 주식회사	다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
US20050096311A1 (en)	2003-10-30	2005-05-05	Cns Response	Compositions and methods for treatment of nervous system disorders
CA2553207A1 (en)	2004-01-13	2005-08-04	Kishore M. Gadde	Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
PE20051156A1 (es)	2004-03-22	2006-02-13	Novartis Ag	Formulaciones de matriz orales que comprenden licarbazepina
PE20060124A1 (es)	2004-03-22	2006-03-07	Novartis Ag	Tabletas de desintegracion que comprenden licarbazepina
GB2416167A (en)	2004-07-13	2006-01-18	Portela & Ca Sa	Chiral inversion and esterification of (S)- and (R)-10-hydroxy-dibenzazepine carboxamides
GB0425320D0 (en)	2004-11-17	2004-12-22	Johnson Matthey Plc	Diamines
GB2422149A (en)	2005-01-14	2006-07-19	Portela & Ca Sa	Process for the preparation of 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide
MX2007013882A (es) *	2005-05-06	2008-01-28	Portela & Ca Sa	Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.
US20060252745A1 (en) *	2005-05-06	2006-11-09	Almeida Jose L D	Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
EP2384755A1 (en) *	2005-05-06	2011-11-09	Bial-Portela & CA, S.A.	Eslicarbazepine acetate and methods of use
GB0515690D0 (en)	2005-07-29	2005-09-07	Portela & Ca Sa	Asymmetric catalytic reduction
GB0603008D0 (en)	2006-02-14	2006-03-29	Portela & Ca Sa	Method
GB2437078A (en)	2006-04-11	2007-10-17	Portela & Ca Sa	10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives
GB0700773D0 (en)	2007-01-15	2007-02-21	Portela & Ca Sa	Drug therapies
US8372431B2 (en)	2007-10-26	2013-02-12	Bial-Portela & C.A., S.A.	Pharmaceutical composition comprising licarbazepine acetate
WO2011031176A1 (en)	2009-09-10	2011-03-17	Bial - Portela & C.A., S.A.	Oral suspension formulations of esclicarbazepine acetate

2007
- 2007-01-15 GB GBGB0700773.5A patent/GB0700773D0/en not_active Ceased
2008
- 2008-01-14 NZ NZ578331A patent/NZ578331A/en not_active IP Right Cessation
- 2008-01-14 UA UAA200908511A patent/UA98133C2/ru unknown
- 2008-01-14 US US12/522,535 patent/US20100048538A1/en not_active Abandoned
- 2008-01-14 CA CA2674303A patent/CA2674303C/en active Active
- 2008-01-14 RU RU2009131075/15A patent/RU2488397C2/ru active
- 2008-01-14 RS RS20161104A patent/RS55475B1/sr unknown
- 2008-01-14 ES ES08705172.8T patent/ES2606952T3/es active Active
- 2008-01-14 CN CNA2008800022840A patent/CN101605571A/zh active Pending
- 2008-01-14 DK DK08705172.8T patent/DK2121138T3/da active
- 2008-01-14 KR KR1020097016940A patent/KR101519040B1/ko active IP Right Grant
- 2008-01-14 AU AU2008205712A patent/AU2008205712B2/en not_active Ceased
- 2008-01-14 WO PCT/PT2008/000002 patent/WO2008088233A1/en active Application Filing
- 2008-01-14 BR BRPI0806568-3A patent/BRPI0806568A2/pt not_active IP Right Cessation
- 2008-01-14 HU HUE08705172A patent/HUE032467T2/en unknown
- 2008-01-14 SI SI200831724A patent/SI2121138T1/sl unknown
- 2008-01-14 MX MX2009007486A patent/MX2009007486A/es active IP Right Grant
- 2008-01-14 JP JP2009545512A patent/JP2010515727A/ja active Pending
- 2008-01-14 EP EP08705172.8A patent/EP2121138B1/en not_active Revoked
- 2008-01-14 EP EP16180742.5A patent/EP3222323A1/en not_active Withdrawn
- 2008-01-14 PT PT87051728T patent/PT2121138T/pt unknown
- 2008-01-14 LT LTEP08705172.8T patent/LT2121138T/lt unknown
- 2008-01-14 PL PL08705172T patent/PL2121138T3/pl unknown
- 2008-01-14 AR ARP080100164A patent/AR064898A1/es unknown
2009
- 2009-07-05 IL IL199697A patent/IL199697A0/en unknown
- 2009-08-05 ZA ZA200905468A patent/ZA200905468B/xx unknown
2013
- 2013-12-19 US US14/134,843 patent/US9763954B2/en active Active
2016
- 2016-12-02 HR HRP20161619TT patent/HRP20161619T1/hr unknown
- 2016-12-08 CY CY20161101268T patent/CY1118297T1/el unknown
2017
- 2017-08-15 US US15/677,165 patent/US20180228812A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP3222323A1 (en)	2017-09-27
RU2009131075A (ru)	2011-02-27
KR20090110909A (ko)	2009-10-23
AU2008205712A1 (en)	2008-07-24
KR101519040B1 (ko)	2015-05-11
UA98133C2 (en)	2012-04-25
HRP20161619T1 (hr)	2017-01-13
PT2121138T (pt)	2016-12-20
IL199697A0 (en)	2010-04-15
CN101605571A (zh)	2009-12-16
LT2121138T (lt)	2016-12-27
US9763954B2 (en)	2017-09-19
GB0700773D0 (en)	2007-02-21
AU2008205712B2 (en)	2013-11-07
HUE032467T2 (en)	2017-09-28
RS55475B1 (sr)	2017-04-28
RU2488397C2 (ru)	2013-07-27
JP2010515727A (ja)	2010-05-13
NZ578331A (en)	2012-03-30
EP2121138A1 (en)	2009-11-25
BRPI0806568A2 (pt)	2014-05-06
CA2674303A1 (en)	2008-07-24
SI2121138T1 (sl)	2017-02-28
US20140309214A1 (en)	2014-10-16
ZA200905468B (en)	2010-05-26
CY1118297T1 (el)	2017-06-28
US20100048538A1 (en)	2010-02-25
MX2009007486A (es)	2009-07-22
US20180228812A1 (en)	2018-08-16
PL2121138T3 (pl)	2017-03-31
ES2606952T3 (es)	2017-03-28
WO2008088233A1 (en)	2008-07-24
AR064898A1 (es)	2009-05-06
EP2121138B1 (en)	2016-09-14
CA2674303C (en)	2017-02-28

Publication	Publication Date	Title
DK2356093T3 (da)	2013-04-22	Carbazolforbindelser og terapeutiske anvendelser af forbindelserne
DK2182863T3 (da)	2012-07-16	Åbningsdilatator
BRPI0916931A2 (pt)	2015-11-24	agentes terapêuticos
DK2111555T3 (da)	2013-09-02	Diagnosticering af præeklampsi
DK2144905T3 (da)	2013-03-11	Terapeutiske midler
DK2035369T3 (da)	2014-10-06	Terapeutiske
DK3005986T3 (da)	2021-11-22	Infusion af lægemidler
BRPI0820677A2 (pt)	2014-10-07	Misturas de compostos pesticidas
DK2358714T3 (da)	2012-08-20	Alkylcyclohexylethere af dihydrotetraazabenzoazulener
DK2114147T3 (da)	2012-06-25	Reduktion af bivirkninger af tramadol
DK2178900T3 (da)	2012-06-25	Oprensning af pegylerede polypeptider
BRPI0820410A2 (pt)	2015-05-19	Lactans substituídos terapêuticos
DK2117565T3 (da)	2012-11-19	Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
BRPI0818598A2 (pt)	2017-05-16	agentes terapêuticos - 802
DK2121138T3 (da)	2017-01-02	Terapeutiske anvendelser af eslicarbazepin
DK2175849T3 (da)	2013-05-13	Behandling af melanomer
ES1064635Y (es)	2007-07-01	Disposicion de conjuntos conmutadores de pulsador
DK2118174T3 (da)	2013-02-25	Anvendelse af tocopherol
BRPI0821567A2 (pt)	2014-12-23	Misturas de compostos pesticidas
BRPI0820650A2 (pt)	2014-10-14	Misturas de compostos pesticidas
DE602008005536D1 (de)	2011-04-28	Herstellung von MnB12H12
DK2109449T3 (da)	2011-09-12	Lægemiddel til behandling af endometriose
DK2173197T3 (da)	2019-09-23	Fremgangsmåde
DE112008002814A5 (de)	2010-07-22	Orthesengelenk
BRPI0909764A2 (pt)	2015-10-06	compostos terapêuticos